Tryp Therapeutics Inc. announced the appointment of Australia-based Jason Carroll as the Company's new Chief Executive Officer, beginning October 1, 2023. Mr. Carroll brings a wealth of experience as a highly regarded life sciences executive, with an impressive 32-year career in the industry. In addition to his most recent role as Managing Director of iNova Pharmaceuticals Philippines, his extensive background includes leadership roles at industry giants Johnson & Johnson, Janssen Pharmaceutica, and Bristol-Myers Squibb.
Tryp Therapeutics Inc. Canadian Securities Exchange
Equities
TRYP
CA89854F1062
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.06 CAD | 0.00% | 0.00% | +50.00% |
1st Jan change | Capi. | |
---|---|---|
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- TYP Stock
- TRYP Stock
- News Tryp Therapeutics Inc.
- Tryp Therapeutics Announces Appointment of Jason Carroll as New Chief Executive Officer, Effective October 1, 2023